João Pedro Ferreira Selected Research

Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)

1/2022	The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
1/2021	Circulating multimarker approach to identify patients with preclinical left ventricular remodelling and/or diastolic dysfunction.
10/2020	Impact of Uric Acid on Hypertension Occurrence and Target Organ Damage: Insights From the STANISLAS Cohort With a 20-Year Follow-up.
11/2019	Nondipping Pattern and Cardiovascular and Renal Damage in a Population-Based Study (The STANISLAS Cohort Study).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

João Pedro Ferreira Research Topics

Disease

181	Heart Failure 05/2024 - 10/2013
31	Myocardial Infarction 12/2023 - 02/2017
20	Fibrosis (Cirrhosis) 03/2024 - 01/2018
20	Type 2 Diabetes Mellitus (MODY) 03/2024 - 01/2020
15	Stroke (Strokes) 12/2023 - 08/2016
13	Inflammation (Inflammations) 01/2024 - 01/2019
12	Hypertension (High Blood Pressure) 12/2022 - 10/2017
11	Atrial Fibrillation 12/2023 - 08/2016
9	Cardiomyopathies (Cardiomyopathy) 04/2024 - 01/2016
9	Chronic Renal Insufficiency 03/2024 - 11/2016
9	Left Ventricular Dysfunction 04/2022 - 01/2018
8	Coronary Artery Disease (Coronary Atherosclerosis) 12/2023 - 05/2017
8	Cardiovascular Diseases (Cardiovascular Disease) 01/2023 - 01/2018
7	Acute Coronary Syndrome 11/2023 - 01/2018
7	Hyperkalemia 01/2023 - 01/2018
6	Respiratory Sounds (Crackle) 11/2022 - 05/2019
5	Diabetes Mellitus 12/2022 - 05/2017
4	Chronic Obstructive Pulmonary Disease (COPD) 01/2024 - 01/2020
4	Chronic Kidney Failure (Chronic Renal Failure) 01/2024 - 01/2017
4	Body Weight (Weight, Body) 07/2023 - 04/2022
4	Obesity 07/2023 - 01/2020
4	Albuminuria 11/2022 - 03/2014
4	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2022 - 11/2019
4	Hemorrhage 01/2021 - 08/2016
4	Hypotension (Low Blood Pressure) 01/2021 - 01/2020
3	COVID-19 03/2024 - 02/2021
3	Necrosis 11/2023 - 01/2022
3	ST Elevation Myocardial Infarction 10/2023 - 01/2018
3	Hypokalemia 01/2023 - 01/2020
3	Gout 01/2023 - 01/2022
3	Acute Kidney Injury (Acute Renal Failure) 01/2023 - 02/2021
3	Anemia 11/2022 - 01/2018
3	Prediabetic State (Prediabetes) 01/2022 - 01/2021
3	Systolic Heart Failure 01/2021 - 01/2018
3	Renal Insufficiency (Renal Failure) 01/2021 - 01/2019
2	Dyspnea (Shortness of Breath) 01/2024 - 09/2023
2	Atherosclerosis 01/2024 - 01/2019
2	Vascular Diseases (Vascular Disease) 10/2023 - 01/2021
2	Overweight 07/2023 - 01/2022
2	Cardiac Sudden Death (Sudden Cardiac Arrest) 01/2023 - 05/2019
2	Weight Loss (Weight Reduction) 01/2023 - 04/2022
2	Hyperuricemia 01/2023 - 01/2022
2	Sudden Death 10/2022 - 11/2020
2	Neoplasms (Cancer) 01/2022 - 01/2019
2	Isolated Systolic Hypertension 11/2021 - 07/2021

Drug/Important Bio-Agent (IBA)

57	empagliflozinIBA 04/2024 - 01/2019
36	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2014
30	Spironolactone (Aldactone)FDA LinkGeneric 03/2024 - 03/2014
21	Brain Natriuretic Peptide (Natrecor)FDA Link 03/2024 - 03/2014
21	Mineralocorticoid Receptor AntagonistsIBA 11/2023 - 01/2014
21	Eplerenone (Inspra)FDA LinkGeneric 01/2023 - 01/2018
16	SodiumIBA 12/2023 - 06/2016
16	Natriuretic PeptidesIBA 12/2023 - 12/2016
15	CreatinineIBA 01/2023 - 11/2016
14	Sodium-Glucose Transport ProteinsIBA 04/2024 - 01/2021
12	pro-brain natriuretic peptide (1-76)IBA 03/2024 - 01/2018
12	Sodium-Glucose Transporter 2 InhibitorsIBA 12/2023 - 01/2020
12	Glucose (Dextrose)FDA LinkGeneric 12/2023 - 01/2020
12	DiureticsIBA 06/2023 - 10/2013
11	PotassiumIBA 01/2023 - 01/2018
10	CollagenIBA 05/2024 - 01/2018
10	Proteins (Proteins, Gene)FDA Link 11/2023 - 01/2019
10	AlbuminsIBA 01/2023 - 01/2018
9	Glucagon-Like Peptide-1 Receptor AgonistsIBA 08/2023 - 01/2022
8	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2023 - 01/2019
6	Insulin (Novolin)FDA Link 04/2024 - 04/2019
6	Troponin T (Troponin T1)IBA 12/2023 - 01/2014
6	Uric Acid (Urate)IBA 01/2023 - 10/2020
6	Procollagen Type IIBA 01/2023 - 01/2019
5	SymportersIBA 12/2023 - 01/2021
5	RivaroxabanIBA 12/2023 - 11/2019
5	procollagen type I carboxy terminal peptide (PICP)IBA 12/2023 - 01/2019
5	Hemoglobins (Hemoglobin)IBA 01/2023 - 04/2016
5	TroponinIBA 11/2022 - 01/2014
5	Angiotensin Receptor AntagonistsIBA 11/2022 - 01/2019
5	alogliptinIBA 07/2021 - 01/2020
4	AldosteroneIBA 10/2023 - 01/2018
4	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2023 - 01/2020
4	Losartan (Cozaar)FDA LinkGeneric 01/2023 - 01/2018
4	Collagen Type I (Type I Collagen)IBA 01/2023 - 01/2021
4	procollagen Type III-N-terminal peptide (PIIP)IBA 01/2022 - 01/2019
4	Collagen Type III (Type III Collagen)IBA 01/2022 - 01/2019
4	Antihypertensive Agents (Antihypertensives)IBA 11/2021 - 05/2017
4	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2021 - 01/2020
4	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2020 - 06/2016
3	C-Reactive ProteinIBA 01/2024 - 01/2022
3	omega-Chloroacetophenone (Mace)IBA 01/2024 - 02/2021
3	Glucagon-Like Peptide 1 (GLP 1)IBA 07/2023 - 01/2022
3	dapagliflozinIBA 01/2023 - 01/2020
3	Neprilysin (Neutral Endopeptidase)IBA 01/2023 - 01/2020
3	Valsartan (Vals)FDA Link 01/2021 - 01/2018
2	Interleukin-6 (Interleukin 6)IBA 01/2024 - 11/2023
2	fibrin fragment D (D-dimer)IBA 12/2023 - 01/2021
2	Growth Differentiation Factor 15IBA 11/2023 - 01/2020
2	AdrenomedullinIBA 11/2023 - 01/2021
2	rGLP-1 proteinIBA 01/2023 - 10/2022
2	Hormones (Hormone)IBA 01/2023 - 11/2022
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2022 - 07/2021

Therapy/Procedure

50	Therapeutics 11/2023 - 10/2013
2	Patient Readmission 01/2023 - 01/2020